IFNγR signaling mediates alloreactive T-cell trafficking and GVHD

Blood

Volumn 120, Issue 19, 2012, Pages 4093-4103

  Choi, Jaebok ^a   Ziga, Edward D ^a   Ritchey, Julie ^a   Collins, Lynne ^b   Prior, Julie L ^b   Cooper, Matthew L ^a   Piwnica Worms, David ^b   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; GAMMA INTERFERON RECEPTOR; JANUS KINASE INHIBITOR;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GASTROINTESTINAL TRACT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IN VITRO STUDY; IN VIVO STUDY; MISMATCH NEGATIVITY; MOUSE; NONHUMAN; ORGAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; WILD TYPE;

EID: 84868606215     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403196     Document Type: Article

References (51)

1. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68(3):770-773. (Pubitemid 16008184)
2. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352. (Pubitemid 46674485)
3. Butturini A, Bortin MM, Gale RP. Graft-versusleukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2(3):233-242.
4. Butturini A, Gale RP. The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transplant. 1987;2(4):351- 354.
5. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus- tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150. (Pubitemid 37173698)
6. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330-336. (Pubitemid 36432314)
7. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061. (Pubitemid 36222930)
8. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337-342. (Pubitemid 36432315)
9. Mowat AM. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology. 1989;68(1):18-23. (Pubitemid 19236063)
10. Lu Y, Waller EK. Dichotomous role of interferongamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant. 2009;15(11):1347- 1353.
11. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of Interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2005;2(5):323-329.
12. Welniak LA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Opposing roles of interferon-gamma on CD4+ T cell-mediated graft-versus-host disease: effects of conditioning. Biol Blood Marrow Transplant. 2000;6(6):604-612.
13. Yang YG, Qi J, Wang MG, Sykes M. Donorderived interferon gamma separates graft-versusleukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood. 2002; 99(11):4207-4215. (Pubitemid 35332067)
14. Burman AC, Banovic T, Kuns RD, et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood. 2007;110(3): 1064-1072. (Pubitemid 47267449)
15. Yi T, Chen Y, Wang L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101-3112.
16. Lu Y, Giver CR, Sharma A, et al. IFN-gamma and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood. 2012;119(4):1075-1085.
17. Robb RJ, Hill GR. The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood. 2012;119(23):5351-5358.
18. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-gamma receptor. Science. 1993;259(5102):1742-1745. (Pubitemid 23114659)
19. Rettig MP, Ritchey JK, Prior JL, Haug JS, Piwnica-Worms D, DiPersio JF. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J Immunol. 2004;173(6): 3620-3630. (Pubitemid 39280721)
20. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus- host disease without sacrificing graft-versus- leukemia. Blood. 2010;116(1):129-139.
21. Heymer B. Histopathological manifestations of acute GvHD. In: Clinical and diagnostic pathology of Graft-versus-host Disease. Berlin, Heidelberg, New York: Springer-Verlag. 2002;52-83.
22. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods. 2005;2(8):607-614. (Pubitemid 41086852)
23. Rettig MP, Ritchey JK, Meyerrose TE, Haug JS, DiPersio JF. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus- host disease. Mol Ther. 2003;8(1):29-41. (Pubitemid 36939294)
24. Hanash AM, Kappel LW, Yim NL, et al. Abrogation of donor T-cell IL-21 signaling leads to tissuespecific modulation of immunity and separation of GVHD from GVL. Blood. 2011;118(2):446-455.
25. Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007;109(7):3115-3123. (Pubitemid 46482115)
26. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10(6):595-602.
27. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232-5240.
28. Wilson LJ. Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat. 2010;20(5):609-623.
29. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versushost disease. Blood. 2005;105(11):4191-4199.
30. Garin MI, Chu CC, Golshayan D, Cernuda- Morollon E,Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2007;109(5):2058-2065. (Pubitemid 46348206)
31. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforinindependent mechanism. J Immunol. 2005; 174(4):1783-1786. (Pubitemid 40223916)
32. Nakamura K, Kitani A, Strober W. Cell contactdependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001; 194(5):629-644. (Pubitemid 32844773)
33. Hasegawa H, Inoue A, Kohno M, et al. Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. Gene Ther. 2008;15(3):171- 182.
34. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003;31(10):897-902. (Pubitemid 37211374)
35. He S, Cao Q, Qiu Y, et al. A new approach to the blocking of alloreactive T cell-mediated graft-versus- host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol. 2008;181(11):7581-7592.
36. Iwasaki M, Mukai T, Nakajima C, et al. A mandatory role for STAT4 in IL-12 induction of mouse T cell CCR5. J Immunol. 2001;167(12):6877- 6883.
37. Lu B, Ebensperger C, Dembic Z, et al. Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc Natl Acad Sci U S A. 1998;95(14):8233- 8238.
38. Swihart K, Fruth U, Messmer N, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4- T cell response. J Exp Med. 1995;181(3):961-971.
39. Mori Y, Kodaka T, Kato T, Kanagawa EM, Kanagawa O. Critical role of IFN-gamma in CFAmediated protection of NOD mice from diabetes development. Int Immunol. 2009;21(11):1291- 1299.
40. Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/ CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000-2009.
41. Oo YH, Weston CJ, Lalor PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184(6):2886-2898.
42. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol. 2004;173(2):845-854. (Pubitemid 38930812)
43. Betts BC, Abdel-Wahab O, Curran SA, et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood. 2011;118(19):5330-5339.
44. Ma H, Lu C, Ziegler J, et al. Absence of Stat1 in donor CD4 T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest. 2011;121(7):2554-2569.
45. Cheong HS, Park CS, Kim LH, et al. CXCR3 polymorphisms associated with risk of asthma. Biochem Biophys Res Commun. 2005;334(4): 1219-1225.
46. Tiroch K, von Beckerath N, Koch W, et al. Interferon-gamma and interferon-gamma receptor 1 and 2 gene polymorphisms and restenosis following coronary stenting. Atherosclerosis. 2005;182(1):145-151. (Pubitemid 41188380)
47. Zhou J, Chen DQ, Poon VK, et al. A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. Immunogenetics. 2009;61(6):423-430.
48. Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res. 2008;28(3):141-152. (Pubitemid 351380148)
49. Bulat-Kardum L, Etokebe GE, Knezevic J, et al. Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A; T-56C) and susceptibility to tuberculosis. Scandinavian J Immunol. 2006;63(2):142-150.
50. Tang NL, Fan HP, Chang KC, et al. Genetic association between a chemokine gene CXCL-10 (IP- 10, interferon gamma inducible protein 10) and susceptibility to tuberculosis. Clin Chim Acta. 2009;406(1-2):98-102.
51. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(11):1882-1890.